Results 51 to 60 of about 9,032 (208)

Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development

open access: yesTaiwan Journal of Ophthalmology, 2020
Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of toxic diffuse goiter (Graves' disease), also known as Graves' ophthalmopathy/orbitopathy. As an organ-specific autoimmune disease, the pathogenesis of TAO is still
Yazhuo Huang   +3 more
doaj   +1 more source

Clinical evaluation of Graves ophthalmopathy [PDF]

open access: yesSrpski Arhiv za Celokupno Lekarstvo, 2012
Introduction. Graves ophthalmopathy is an autoimmune disease, which is the consequence of thyroid dysfunction. Ocular manifestations occur in 50% of patients with Graves disease.
Janićijević-Petrović Mirjana A.   +5 more
doaj   +1 more source

The thyroid, the eyes and the gut: a possible connection [PDF]

open access: yes, 2017
Graves’ disease (GD) is an autoimmune disorder responsible for 60–90% of thyrotoxicosis, with an incidence of 1 to 2 cases per 1000 population per year in England.
Covelli, D., Ludgate, Marian Elizabeth
core   +2 more sources

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition (Adv. Sci. 4/2026)

open access: yesAdvanced Science, Volume 13, Issue 4, 19 January 2026.
An Allosteric Strategy for Thyroid Eye Disease This illustration depicts an aptamer (purple) binding to the target protein (white) at an allosteric site. This strategic binding induces a conformational change that acts as a shield, preventing pathogenic autoantibodies (red) from initiating the disease cascade, while leaving the protein's normal ...
Yanchen Zhang   +16 more
wiley   +1 more source

Pulse dexamethasone therapy versus pulse methylprednisolone therapy for treatment of Graves′s ophthalmopathy

open access: yesIndian Journal of Endocrinology and Metabolism, 2013
Pulse methylprednisolone therapy is the recommended therapy for moderate to severe and active ophthalmopathy, but high dose pulse methylprednisolone therapy is marred by the chances of fulminant hepatic failure and the high cost of therapy. Dexamethasone
Rajeev Philip   +5 more
doaj   +1 more source

Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy [PDF]

open access: yes, 2015
The CXC chemokine receptor (CXCR) 3 and its chemokines (CXCL9, CXCL10, CXCL11) are involved in the pathogenesis of autoimmune disesases. Under the influence of interferon (IFN) γ, the IFNγ-inducible chemokines are secreted by lymphocytes, and by ...
Antonelli, Alessandro   +4 more
core   +1 more source

Exploring the Therapeutic Mechanism of Xiehuo Pingtu San in Treating Thyroid Eye Disease Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

open access: yesInternational Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang   +6 more
wiley   +1 more source

Postural variation of exophthalmometry in Graves′ ophthalmopathy

open access: yesIndian Journal of Ophthalmology, 1990
30 patients with Graves′ ophthalmopathy were subjected to exophthalmometry in the upright and supine positions to determine if the difference in exophthalmometer readings in these two situations are significantly different and would help in ...
Asad Rajvardhan   +3 more
doaj  

Early Low‐Dose Rituximab for Mild‐to‐Moderate Thyroid Eye Disease: A Preliminary Evaluation of Efficacy and Safety

open access: yesInternational Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Thyroid eye disease (TED) is an autoimmune inflammatory condition linked to thyroid dysfunction, which can result in disfigurement and potential vision loss. Recently, immunomodulatory therapies such as rituximab have demonstrated potential benefit in managing TED.
Ming Lu   +3 more
wiley   +1 more source

Miosite do músculo reto medial como forma atípica de apresentação de linfoma tipo MALT: relato de caso [PDF]

open access: yes, 2014
Here we describe the rare case of a 55-year-old man with medial rectus muscle myositis as an atypical presentation of non-Hodgkin B-cell mucosa-associated lymphoma (MALT).
Dittrich, Mirtha Alicia Ramirez   +4 more
core   +4 more sources

Home - About - Disclaimer - Privacy